Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma.
暂无分享,去创建一个
T. Cloughesy | L. Liau | P. Nghiemphu | Le Zhang | H. Kornblum | F. Pajonk | A. Ioannidis | Kruttika Bhat | Ling He | N. T. Nguyen | J. Allen | J. Allen
[1] M. Pellegrini,et al. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma , 2020, Proceedings of the National Academy of Sciences.
[2] A. Pastor,et al. Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment , 2019, Cells.
[3] M. Mehta,et al. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. , 2019, Neuro-oncology.
[4] S. Khatua,et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201 , 2019, Journal of Neuro-Oncology.
[5] S. Libutti,et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration , 2019, Journal of Immunotherapy for Cancer.
[6] Andrew B. Leber,et al. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. , 2019, Cancer cell.
[7] F. Azuaje,et al. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment , 2019, Nature Communications.
[8] M. Mehta,et al. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. , 2019, Journal of neurosurgery. Pediatrics.
[9] Bin Zhang,et al. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment , 2019, EBioMedicine.
[10] Michael L. Wang,et al. Integrated stress response and immune cell infiltration in an ibrutinib‐refractory mantle cell lymphoma patient following ONC201 treatment , 2019, British journal of haematology.
[11] Atique U. Ahmed,et al. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma , 2019, The Journal of Neuroscience.
[12] Yue-hua Chen,et al. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment , 2019, Drug delivery.
[13] A. Kim,et al. Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma , 2018, Front. Oncol..
[14] N. Neamati,et al. Current Challenges and Opportunities in Treating Glioblastoma , 2018, Pharmacological Reviews.
[15] U. McDermott,et al. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies , 2018, Cell cycle.
[16] Neel S. Madhukar,et al. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors , 2017, PloS one.
[17] Wei Li,et al. Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells , 2017, Journal of molecular cell biology.
[18] P. Wen,et al. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma , 2017, Oncotarget.
[19] R. DiPaola,et al. First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors , 2017, Clinical Cancer Research.
[20] C. Gasch,et al. Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention , 2017, Molecular Cancer.
[21] Erwin G. Van Meir,et al. Overcoming therapeutic resistance in glioblastoma: the way forward. , 2017, The Journal of clinical investigation.
[22] A. Idbaih,et al. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma , 2016, Expert review of neurotherapeutics.
[23] J. Lemée,et al. Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. , 2015, Neuro-oncology.
[24] Atique U. Ahmed,et al. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence , 2015, Expert review of neurotherapeutics.
[25] J. Rich,et al. Cancer stem cells in glioblastoma , 2015, Genes & development.
[26] W. El-Deiry,et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway , 2015, Molecular Cancer.
[27] Bernard Rogister,et al. Glioblastoma-Initiating Cells: Relationship with Neural Stem Cells and the Micro-Environment , 2013, Cancers.
[28] K. Makino,et al. Glioma Initiating Cells Form a Differentiation Niche Via the Induction of Extracellular Matrices and Integrin αV , 2013, PloS one.
[29] Atique U. Ahmed,et al. Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies , 2013, Expert review of neurotherapeutics.
[30] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[31] E. Messaris,et al. Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects , 2013, Science Translational Medicine.
[32] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[33] Erika Pastrana,et al. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. , 2011, Cell stem cell.
[34] S. Lyle,et al. Quiescent, Slow-Cycling Stem Cell Populations in Cancer: A Review of the Evidence and Discussion of Significance , 2010, Journal of oncology.
[35] K. Miyazono,et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. , 2009, Cell stem cell.
[36] Giuseppe Trapani,et al. New strategies to deliver anticancer drugs to brain tumors , 2009, Expert opinion on drug delivery.
[37] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[38] L. Ricci-Vitiani,et al. Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.
[39] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[40] Daniel H. Geschwind,et al. Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] N. Laperriere,et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[42] Benedick A Fraass,et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.